替雷利珠单抗联合化疗治疗三阴性乳腺癌的疗效分析

Abstract: Objective To analyze the clinical efficacy of tislelizumab combined with chemotherapy in the treatment of patients with triple-negative breast cancer. Methods Forty patients with triple-negative breast cancer who were diagnosed in our hospital from January 2021 to January 2022 and were scheduled to receive chemotherapy treatment were selected as the research subjects. They were divided into the reference group (only receiving chemotherapy, n＝20) and the experimental group (chemotherapy + tislelizumab treatment, n＝20) by the random number table method. Observe the disease control rates, incidence of adverse reactions and changes in tumor markers levels of the two groups. Results The disease control rate was 75.00% in the experimental group and 40.00% in the reference group. The difference between the groups was statistically significant (P＜0.05). The total incidence of adverse reactions was 70.00% in the experimental group and 55.00% in the reference group, with no statistically significant difference (P＞0.05). There was no statistically significant difference in the levels of tumor markers between the two groups before treatment (P＞0.05). After treatment, all levels decreased significantly (P＜0.05), and compared with the reference group in the same period, the levels of tumor markers in the experimental group were lower after treatment (P＜0.05). Conclusion For patients with triple-negative breast cancer undergoing chemotherapy, tislelizumab as a therapeutic drug can help them further control disease progression without significantly increasing adverse reactions and is more conducive to regulating tumor marker levels.